新生児型Fc受容体（FcRn）は、母体由来IgGの輸送とIgGの分解防止の両方において重要な役割を果たします。

Bispecific antibody-drug conjugates (BsADCs) are a new class of therapeutic drugs being developed to fight cancer. They combine the dual targeting ability of bispecific antibodies with the cell-killing power of cytotoxic drugs. BsADCs are designed to deliver cytotoxic drugs directly to cancer cells, while minimizing damage to healthy cells. While they are still in development, several exciting advances have occurred recently.

今回のエピソードでは、二重特異性抗体およびその他の多特異性フォーマットについて解説します。